Literature DB >> 26536049

Hospital-based Clostridium difficile infection surveillance reveals high proportions of PCR ribotypes 027 and 176 in different areas of Poland, 2011 to 2013.

Hanna Pituch1, Piotr Obuch-Woszczatyński, Dominika Lachowicz, Dorota Wultańska, Paweł Karpiński, Grażyna Młynarczyk, Sofie M van Dorp, Ed J Kuijper.   

Abstract

As part of the European Clostridium difficile infections (CDI) surveillance Network (ECDIS-Net), which aims to build capacity for CDI surveillance in Europe, we constructed a new network of hospital-based laboratories in Poland. We performed a survey in 13 randomly selected hospital-laboratories in different sites of the country to determine their annual CDI incidence rates from 2011 to 2013. Information on C. difficile laboratory diagnostic testing and indications for testing was also collected. Moreover, for 2012 and 2013 respectively, participating hospital-laboratories sent all consecutive isolates from CDI patients between February and March to the Anaerobe Laboratory in Warsaw for further molecular characterisation, including the detection of toxin-encoding genes and polymerase chain reaction (PCR)-ribotyping. Within the network, the mean annual hospital CDI incidence rates were 6.1, 8.6 and 9.6 CDI per 10,000 patient-days in 2011, 2012, and 2013 respectively. Six of the 13 laboratories tested specimens only on the request of a physician, five tested samples of antibiotic-associated diarrhoea or samples from patients who developed diarrhoea more than two days after admission (nosocomial diarrhoea), while two tested all submitted diarrhoeal faecal samples. Most laboratories (9/13) used tests to detect glutamate dehydrogenase and toxin A/B either separately or in combination. In the two periods of molecular surveillance, a total of 166 strains were characterised. Of these, 159 were toxigenic and the majority belonged to two PCR-ribotypes: 027 (n=99; 62%) and the closely related ribotype 176 (n=22; 14%). The annual frequency of PCR-ribotype 027 was not significantly different during the surveillance periods (62.9% in 2012; 61.8% in 2013). Our results indicate that CDIs caused by PCR-ribotype 027 predominate in Polish hospitals participating in the surveillance, with the closely related 176 ribotype being the second most common agent of infection.

Entities:  

Keywords:  PCR-ribotype 027 and 176; Polish surveillance programme of Clostridium difficile infection (CDI); incidence of CDI

Mesh:

Substances:

Year:  2015        PMID: 26536049     DOI: 10.2807/1560-7917.ES.2015.20.38.30025

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  14 in total

Review 1.  Clostridium difficile infection.

Authors:  Wiep Klaas Smits; Dena Lyras; D Borden Lacy; Mark H Wilcox; Ed J Kuijper
Journal:  Nat Rev Dis Primers       Date:  2016-04-07       Impact factor: 52.329

2.  Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015.

Authors:  M Krutova; J Matejkova; P Drevinek; E J Kuijper; O Nyc
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-05       Impact factor: 3.267

3.  Antimicrobial effects of Manuka honey on in vitro biofilm formation by Clostridium difficile.

Authors:  M Piotrowski; P Karpiński; H Pituch; A van Belkum; P Obuch-Woszczatyński
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-18       Impact factor: 3.267

4.  Clinical features and characteristics of Clostridium difficile PCR-ribotype 176 infection: results from a 1-year university hospital internal ward study.

Authors:  Jiri Drabek; Otakar Nyc; Marcela Krutova; Jan Stovicek; Jana Matejkova; Radan Keil
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-12-23       Impact factor: 3.944

5.  Management of a cluster of Clostridium difficile infections among patients with osteoarticular infections.

Authors:  Jacqueline Färber; Sebastian Illiger; Fabian Berger; Barbara Gärtner; Lutz von Müller; Christoph H Lohmann; Katja Bauer; Christina Grabau; Stefanie Zibolka; Dirk Schlüter; Gernot Geginat
Journal:  Antimicrob Resist Infect Control       Date:  2017-02-15       Impact factor: 4.887

6.  A global to local genomics analysis of Clostridioides difficile ST1/RT027 identifies cryptic transmission events in a northern Arizona healthcare network.

Authors:  Charles H D Williamson; Nathan E Stone; Amalee E Nunnally; Heidie M Hornstra; David M Wagner; Chandler C Roe; Adam J Vazquez; Nivedita Nandurkar; Jacob Vinocur; Joel Terriquez; John Gillece; Jason Travis; Darrin Lemmer; Paul Keim; Jason W Sahl
Journal:  Microb Genom       Date:  2019-05-20

7.  Fructooligosaccharides and mannose affect Clostridium difficile adhesion and biofilm formation in a concentration-dependent manner.

Authors:  Michał Piotrowski; Dorota Wultańska; Piotr Obuch-Woszczatyński; Hanna Pituch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-30       Impact factor: 3.267

8.  The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile.

Authors:  Dorota Wultańska; Michał Piotrowski; Hanna Pituch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-03-05       Impact factor: 3.267

9.  Hospital-Wide Surveillance of Healthcare-Associated Infections as a Source of Information about Specific Hospital Needs. A 5-Year Observation in a Multiprofile Provincial Hospital in the South of Poland.

Authors:  Małgorzata Kołpa; Marta Wałaszek; Anna Różańska; Zdzisław Wolak; Jadwiga Wójkowska-Mach
Journal:  Int J Environ Res Public Health       Date:  2018-09-07       Impact factor: 3.390

10.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.